# U-PLEX<sup>®</sup> Human ICOS

#### www.mesoscale.com®

Ordering	Information
----------	-------------

MSD Customer Service Phone: 1-240-314-2795 : 1-301-990-2776 Email: CustomerService@ mesoscale.com

#### Scientific Support

Phone: 1-240-314-2798 Email: ScientificSupport@ mesoscale.com

#### **Company Address**


Meso Scale Discovery, a divistion of Meso Scale Diagnostics

, LLC. 1601 Research Boulevard Rockville, MD 20850-3173 USA

om®	Product Options	Catalog Number	Description		
	Multiplex	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (human)		
1		K151AHBK-1/-2/-4	U-PLEX Human ICOS Assay with SECTOR™ plates		
E	Singleplex	K151AHBK-21/-22/-24	U-PLEX Human ICOS Assay with QuickPlex Ultra <sup>™</sup> plates		
5 6		K251AHBK-2/-4	U-PLEX Human ICOS Assay with 384-well plates		
@	Antibody Set	B21AHB-2/-3	U-PLEX Human ICOS Antibody Set		
Protocol		U-PLEX Product Inserts are available at <u>www.mesoscale.com</u> .			

The U-PLEX<sup>®</sup> platform was designed to provide ultimate flexibility for the detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX Human ICOS Assay tested on U-PLEX plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

# **Representative Calibration Curve and Sensitivity**



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)	
ICOS	1.78	1.3–2.9	


The Calibrator curve was fitted with a 4-parameter logistic model with a  $1/Y^2$  weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

# Precision

Control Average Conc. (pg/mL)		Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)	
High	1,100	1.8	8.7	
Mid 367		1.8	6.9	
Low	131	2.0	9.1	

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only. Not for use in diagnostic procedures.





# MSD® U-PLEX Human ICOS

# Tested Samples

Sample Type	Serum (N = 9)	EDTA Plasma (N = 9)	Citrate Plasma (N = 9)	Normal Lysate (N = 5)	Tumor Lysate (N = 5)
Median (pg/mL)	ND	ND	ND	53	13
Range (pg/mL)	ND	ND	ND	7.3–141	1.2–947
% Detected	0	0	0	80	40

Normal serum and plasma samples were diluted 4-fold prior to the assay. Lysates were tested at a protein concentration of 0.5 mg/mL. ND = non-detectable (<LLOD).

# **Dilution Linearity**

Serum			EDTA Plasma		
Fold Dilution Average % Recovery % Recovery Range		Fold Dilution Average % Recovery % Recover		% Recovery Range	
2	81	75–86	2	79	75–83
8	106	104–109	8	108	104–112
16	111	107–115	16	116	110–125

Samples were spiked with calibrator and serially diluted. Percent recovery at each dilution was normalized to the dilution-adjusted 4 (or 100)-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration)  $x \ 100$ 

#### Spike Recovery

	Ser	um	EDTA Plasma	
Spike Level	Average % Recovery % Recovery Range		Average% Recovery	% Recovery Range
High	86	79–96	89	80–106
Mid	92	85–97	92	83–106
Low	93	89–100	90	69–106

Samples were spiked with calibrator at three levels within the range of the assay.

% Recovery = (measured concentration / expected concentration) x 100

# Specificity

To assess specificity, the ICOS Antibody Set was tested individually against a larger panel of analytes for nonspecific binding: APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD276/B7-H3, CD28, CD40L (soluble), CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, G-CSF, Galectin-9, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOSL/B7-H2, IFN- α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL 25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-2Rα, IL-3, IL-31, IL-33, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, LAG-3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9, Nectin-4, 0X40/TNFRSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, TARC, Tie-2, TIGIT, TLR-1, TNF-RI, TNF-RI, TNF-β, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/FIt-1 and YKL-40. Nonspecific binding was less than 2.0%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

# **Diluent Compatibility**

Diluents 58 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

#### **Assay Components**

Calibrator: ICOS is included in Calibrator 28. The human ICOS Calibrator is a full-length recombinant protein expressed in a mouse cell line.

Antibodies: The U-PLEX Human ICOS Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.

#### Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

MESO SCALE DISCOVERY, MESO SCALE DIAGNOSTICS, www.mesoscale.com, MSD, MSD (design), U-PLEX, U-PLEX (design), 96 WELL SMALL-SPOT (design), QuickPlex Ultra, SECTOR, and Spot the Difference are trademarks and/or service marks of Meso Scale Diagnostics, LLC. ©2016-2025 Meso Scale Diagnostics, LLC. All rights reserved.

